Institute for Diabetes and Organoid Technology
The focus of the Institute for Diabetes and Organoid Technology (IDOT) is to understand and modify the mechanisms underlying pancreas development and function with the goal to improve disease progression and outcome. We utilize organoid systems derived from human pluripotent stem cells as well as mouse models to study pancreas biology, diabetes and pancreatic cancer, with the goal to prevent or reverse disease-related pathological processes.
The focus of the Institute for Diabetes and Organoid Technology (IDOT) is to understand and modify the mechanisms underlying pancreas development and function with the goal to improve disease progression and outcome. We utilize organoid systems derived from human pluripotent stem cells as well as mouse models to study pancreas biology, diabetes and pancreatic cancer, with the goal to prevent or reverse disease-related pathological processes.
Recent publications
See all2023 Nature Communications
Sox9 regulates alternative splicing and pancreatic beta cell function
2023 Seminars in Nephrology
2023 Nature Communications
Stem cell-derived islet therapy: is this the end of the beginning?
2023 JCI Insight
2023 American Institute of Chemical Engineers
2022 JCI Insight
β Cell-specific deletion of Zfp148 improves nutrient-stimulated β cell Ca2+ responses
2022 Human Gene Therapy
2022 Stem Cell Reports
Development of a scalable method to isolate subsets of stem cell-derived pancreatic islet cells
2022 Cold Spring Harbor Perspectives in Biology
2021 Cell Reports
2021 Journal of Biomedical Materials Research
2021 eLife
Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree
2021 Frontiers in Endocrinology
2021 Biotechnology and Bioengineering